Want to see HK:2170 full AI Analyst Report?
Top Page
Suzhou Basecare Medical Corp. Ltd. Class H
(2170)
Select Model
Select Model
Rating:42Neutral
Price Target:
HK$1.50
▼(-23.86% Downside)
Action:Reiterated
Date:06/30/26
The score is primarily held down by poor financial performance—large ongoing losses, persistent cash burn, and a 2025 revenue decline—combined with bearish technical trends (price below key moving averages and negative MACD). The balance sheet’s moderate leverage and a negative P/E (loss-making) provide limited offset, resulting in an overall low score.
Positive Factors
Specialized ART Medical Device Platform
A focused product platform serving IVF and fertility-treatment workflows can support clinical expertise, customer relationships, and recurring usage of procedure-related consumables. These characteristics may provide durable positioning within a specialized medical-device niche.
Negative Factors
Persistent Deep Operating Losses
Extremely negative operating and net margins show that the current cost structure is not supported by revenue. Unless operating expenses decline materially or sales accelerate, sustained losses could consume equity and limit the company’s ability to invest.
Read all positive and negative factors
Positive Factors
Negative Factors
Specialized ART Medical Device Platform
A focused product platform serving IVF and fertility-treatment workflows can support clinical expertise, customer relationships, and recurring usage of procedure-related consumables. These characteristics may provide durable positioning within a specialized medical-device niche.
Read all positive factors
Suzhou Basecare Medical Corp. Ltd. Class H (2170) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$376.10M
Dividend YieldN/A
Average Volume (3M)56.28K
Price to Earnings (P/E)―
Beta (1Y)1.34
Revenue Growth-2.28%
EPS Growth24.76%
CountryHK
Employees388
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.82
Shares Outstanding82,713,840
10 Day Avg. Volume121,800
30 Day Avg. Volume56,283
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)0.49
Price to Sales (P/S)1.96
P/FCF Ratio-1.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$1.60Price Target Upside-18.78% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.23
Revenue Forecast (FY)HK$412.00M
Suzhou Basecare Medical Corp. Ltd. Class H Business Overview & Revenue Model
Company Description
Suzhou Basecare Medical Corporation Limited, an investment holding company established in Suzhou, China, in 2010, focuses its business activities within the People's Republic of China. The company primarily engages in the research, development, an...
How the Company Makes Money
The company makes money primarily by selling ART medical devices and consumables to hospitals, fertility clinics, and IVF laboratories. Its revenue model is product-based: (1) recurring revenue from consumables used per procedure and routine lab o...
Suzhou Basecare Medical Corp. Ltd. Class H Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 233.27M | 299.11M | 207.98M | 140.90M | 107.30M |
| Gross Profit | 123.61M | 136.22M | 91.35M | 59.53M | 51.15M |
| EBITDA | -166.99M | -253.30M | -174.14M | -117.73M | -118.88M |
| Net Income | -223.46M | -237.03M | -191.69M | -123.16M | -143.65M |
Balance Sheet | |||||
| Total Assets | 1.45B | 1.67B | 1.90B | 1.78B | 1.80B |
| Cash, Cash Equivalents and Short-Term Investments | 447.34M | 684.63M | 945.71M | 1.33B | 1.52B |
| Total Debt | 343.51M | 328.42M | 281.92M | 75.54M | 48.57M |
| Total Liabilities | 512.00M | 527.47M | 499.98M | 188.33M | 85.85M |
| Stockholders Equity | 935.06M | 1.14B | 1.40B | 1.59B | 1.72B |
Cash Flow | |||||
| Free Cash Flow | -243.37M | -322.41M | -371.44M | -317.52M | -234.71M |
| Operating Cash Flow | -160.01M | -229.12M | -267.23M | -188.77M | -197.85M |
| Investing Cash Flow | -5.33M | -181.19M | -324.81M | -88.70M | -56.60M |
| Financing Cash Flow | 16.13M | 33.78M | 190.55M | 23.51M | 1.60B |
Suzhou Basecare Medical Corp. Ltd. Class H Technical Analysis
Negative
1.97
Price Trends
1.39
Negative
1.52
Negative
1.78
Negative
Market Momentum
>-0.01
Negative
49.73
Neutral
89.74
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2170, the sentiment is Negative. The current price of 1.97 is above the 20-day moving average (MA) of 1.38, above the 50-day MA of 1.39, and above the 200-day MA of 1.78, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 49.73 is Neutral, neither overbought nor oversold. The STOCH value of 89.74 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2170.
Suzhou Basecare Medical Corp. Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | HK$5.56B | 12.60 | 13.24% | 2.35% | 16.15% | 31.89% | |
59 Neutral | HK$5.98B | 92.46 | 1.72% | ― | 0.75% | -20.22% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | HK$1.63B | -0.86 | -6.69% | ― | ― | ― | |
42 Neutral | HK$376.10M | -1.43 | -22.71% | ― | -2.28% | 24.76% | |
37 Underperform | HK$538.03M | -0.98 | -28.24% | ― | -38.15% | 25.70% | |
35 Underperform | HK$11.65B | 31.24 | 6.07% | 0.06% | -3.62% | ― |
* Healthcare Sector Average
HK:2170
Suzhou Basecare Medical Corp. Ltd. Class H
1.38
-2.18
-61.27%
HK:0853
MicroPort Scientific
6.08
-8.33
-57.81%
HK:1302
LifeTech Scientific Corporation
1.39
-0.62
-30.75%
HK:1789
AK Medical Holdings Ltd.
5.02
-0.75
-13.04%
HK:2160
MicroPort CardioFlow Medtech Corp.
1.28
-6.22
-82.93%
HK:2500
Venus Medtech (Hangzhou), Inc. Class H
1.22
-2.88
-70.24%
Suzhou Basecare Medical Corp. Ltd. Class H Corporate Events
Suzhou Basecare Board to Review Interim Results and Possible Dividend
Aug 18, 2026
Suzhou Basecare Medical Corporation Limited, a Hong Kong-listed healthcare company based in Suzhou, operates through a group structure that includes several subsidiaries and is governed by a board made up of executive, non-executive and independen...
Suzhou Basecare Cuts Losses as Genetic Testing and Culture Media Drive Revenue Surge
Aug 16, 2026
Suzhou Basecare Medical Corporation Limited expects significant improvement in its interim 2026 results, with revenue projected to rise to about RMB125.7 million to RMB130.8 million, a 24% to 29% increase year-on-year. The loss attributable to equ...
Suzhou Basecare Shareholders Approve All Resolutions at 2025 AGM
Jun 4, 2026
Suzhou Basecare Medical Corporation Limited, a PRC-incorporated medical company listed on the Hong Kong Stock Exchange, operates through a group structure and relies on international auditing standards. The company is overseen by a board of direct...
Suzhou Basecare Wins NMPA Approval, Completes Certification of Gems IVF Reagent Line
May 29, 2026
Suzhou Basecare Medical Corporation Limited has secured NMPA approval in China for its Class III medical device registration certificate covering the Gems series egg retrieval solution, a core reagent used at the outset of IVF procedures. The solu...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.